STM-Structure Seasch 3.4.05

=> d ibib abs hitstr 1-15

ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:

2003:454295 CAPLUS

DOCUMENT NUMBER:

139:52892

TITLE:

Preparation of 2-(2-methyl-1,2,3,4-

tetrahydroisoguinolin-4-yl)phenyls as sodium ion

proton antiporter (NHE) inhibitors

INVENTOR(S):

Hofmeister, Armin; Heinelt, Uwe; Lang, Hans-Jochen;

Bleich, Markus; Wirth, Klaus; Gekle, Michael

PATENT ASSIGNEE(S):

Aventis Pharma Deutschland GmbH, Germany

SOURCE:

PCT Int. Appl., 304 pp.

Patent

CODEN: PIXXD2

DOCUMENT TYPE: LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA'	TENT	NO.			KIN	D	DATE			APP:	LICAT	ION 1	NO.		D	ATE	
MO	2003	0481	29		A1	-	2003	0612		WO :	2002-:	EP12	990		2	0021	120
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB	, BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC	, EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE	, KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN	, MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SI	, SK,	SL,	TJ,	TM,	TN,	TR,	TT,
							VN,										
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ	, TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,
		KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG	, CH,	CY,	CZ,	DE,	DK,	EE,	ES,
											, PT,				BF,	ВJ,	CF,
		CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR	, NE,	SN,	TD,	TG			
EP	1453										2002-					0021	
•	R:										, IT,					MC,	PT,
											, TR,						
BR	2002	0147	53		Α	,	2004	1214		BR :	2002-:	1475	3		2	0021	120
	2004										2002-3					0021	204
										US :	2004-8	3668	43		2	0040	614
PRIORITY	Y APP	LN.	INFO	. :						DE :	2001-:	1015	9714	i	A 2	0011	205
									1	US :	2002-3	3535	13P		P 2	0020	201
									1	WO :	2002-1	EP12	990	1	₩ 2	0021	120
										US :	2002-3	3093!	52	7	A3 2	0021	204
OTHER SO	OURCE	(S):			MAR:	PAT	139:	52892	2								

GI

^{*} STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Title compds. I [R1, R2, R3, R4 = H, halo, CN, etc.; R5 = H, CpH2p+1, AB CssH2ss-1, etc.; p = 1-8; ss = 3-8; R6 = H, halo, OH, etc.; R7, R8, R9 = Ov-SOw-R23; v = 0, 1; w = 0-2, R23 = OH, CnnH2nn+1, CmmH2mm-1, etc.; nn = 1-8] and their pharmaceutically acceptable salts were prepared For example, acid catalyzed intramol. Pictet Spengler cyclization of benzyl alc. II, prepared from N-methyl-2,4-dichlorobenzylamine in 3-steps, afforded claimed phenyltetrahydroisoquinoline III. In proton sodium antiporting protein (NHE3) inhibition studies, 27-examples of compds. I exhibited IC50 values ranging from 0.024-1.507 $\mu M,\ \text{e.g.,}$ the IC50 value of phenyltetrahydroisoquinoline III hydrochloride was 0.075 μM. Compds. I can also influence serum lipoproteins and can be used for the regression of atherosclerotic alterations.

isoquinolinyl)phenyl]-1-(methylsulfonyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

543736-33-0 CRN

CMF C23 H27 C12 N3 O3 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:

2002:51467 CAPLUS

DOCUMENT NUMBER:

136:118393

TITLE:

Preparation and use of furan-fused-4-phenyl

substituted tetrahydroisoguinolines for treatment of

attention deficit hyperactivity disorder (ADHD)

INVENTOR(S):

Beck, James P.; Pechulis, Anthony D.; Harms, Arthur E.

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA PCT Int. Appl., 116 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT	NO.		KINI)	DATE		i	APPL	ICAT	ION I	NO.		D	ATE	
				-											
WO 2002	004455	5	A2	:	2002	0117	1	WO 2	001-1	US21	818		20	0010	711
WO 2002	004455	5	A3		2002	0620									
W :	AE, A	G, AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
	co, c	CR, CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		R, HU,													
		T, LU,													

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG CA 2415532 AA 20020117 CA 2001-2415532 20010711 US 2002091134 **A1** 20020711 US 2001-902845 20010711 EP 1299393 20030409 EP 2001-952616 A2 20010711 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR BR 2001012350 20030624 BR 2001-12350 20010711 Α JP 2002-509320 JP 2004502774 T2 20040129 20010711 NZ 523456 NZ 2001-523456 Α 20041126 20010711 PRIORITY APPLN. INFO.: US 2000-217412P Ρ 20000711 WO 2001-US21818 W 20010711

OTHER SOURCE(S):

MARPAT 136:118393

GI

$$\mathbb{R}^4$$
 \mathbb{R}^5
 \mathbb{R}^6
 \mathbb{R}^7
 \mathbb{R}^7
 \mathbb{R}^7
 \mathbb{R}^7
 \mathbb{R}^1
 \mathbb{R}^2
 \mathbb{R}^2
 \mathbb{R}^1

AB Title compds. I [R1 = alk(en/yn)yl, cycloalkyl, 5-cycloalkylalkyl andbenzyl, each of which is optionally substituted with 1 to 3 substituents; R2 = H, alk(en/yn)yl, cycloalkyl, cycloalkylalkyl and haloalkyl; R3 = H, halo, alkyl, haloalkyl and cycloalkyl, wherein alkyl, haloalkyl and cycloalkyl are optionally substituted with 1 to 3 substituents selected from alkoxy and amino; R4-6 = H, halo, alkoxy, NO2, amino, amido, ureido, S(0)n, CN, acyl, carboxy, carboxamide, alk(en/yn)yl, cycloalkyl and cycloalkylalkyl; alternatively R5-6 = O-alkyl-O; R7 = H, halo and alkoxy; X = 0, NH (and substituted derivs.) and S; n = 0 - 2] with some provisos, were prepared E.g., 7-formylbenzofuran was converted to the corresponding methylamino-Me derivative (MeOH, MeNH2, NaBH4), alkylated with p-chlorophenacyl bromide (CH2Cl2, Et3N) and reduced to the amino alc. (CH2Cl2, NaBH4, 5 h, $0^{\circ} \rightarrow \text{room temperature}$). This intermediate was treated dropwise with MsOH (CH2Cl2, 0°C → reflux, overnight) to give II as a yellow oil (18% overall yield). Over 150 synthetic examples were provided. Compds. I are selective neurotransmitter receptor binding ligands (no data). I are useful in the treatment of attention-deficit hyperactivity disorder.

389844-43-3P 389845-23-2P IT

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; preparation and use of furan-fused-4-Ph substituted tetrahydroisoquinolines for treatment of attention deficit hyperactivity disorder (ADHD))

RN 389844-43-3 CAPLUS

CN Thieno[2,3-h]isoquinoline, 1,2,3,4-tetrahydro-2-methyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)

HCl

RN 389845-23-2 CAPLUS

CN Thieno[2,3-f]isoquinoline, 6,7,8,9-tetrahydro-7-methyl-9-phenyl-, hydrochloride (9CI) (CA INDEX NAME)

● HCl

L6 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:

2001:338496 CAPLUS

DOCUMENT NUMBER:

134:353258

TITLE:

Aryl- and heteroaryl-substituted

tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin

INVENTOR(S):

Beck, James P.; Curry, Matt A.; Smith, Mark A.

PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA

SOURCE:

PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT	NO.			KIN	D :	DATE		į	APPL	CAT	ION	NO.		D	ATE	
WO 2001	03262	 25		A1	-	2001	 0510	,	WO 2	 000-1	 US30:	 329		2	0001	103
W:	AU, PL, TJ,	RO,	CA,	CN,	CZ,	EE, TR,	HU, UA,	IL, VN,	IN, ZA,	JP, AM,	KR, AZ,	LT, BY,	LV, KG,	MX, KZ,	NO, MD,	NZ, RU,
RW:	AT, PT,	BE, SE,		CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,

CA 2389306 AA 20010510 CA 2000-2389306 20001100 BR 2000015320 A 20020709 BR 2000-15320 20001100 EP 1246806 A1 20021009 EP 2000-976885 20001100 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, POR IE, SI, LT, LV, FI, RO, CY, TR JP 2003513074 T2 20030408 JP 2001-534777 200011000	
EP 1246806 A1 20021009 EP 2000-976885 20001103 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, P' IE, SI, LT, LV, FI, RO, CY, TR	.03
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, P'IE, SI, LT, LV, FI, RO, CY, TR	103
IE, SI, LT, LV, FI, RO, CY, TR	103
	PT,
JP 2003513074 T2 20030408 JP 2001-534777 2000110	
	.03
US 2002143014 A1 20021003 US 2002-91949 20020300	306
US 6579885 B2 20030617	
US 2003203920 A1 20031030 US 2003-426097 20030429	29
US 2005020597 A1 20050127 US 2004-917801 20040813	313
PRIORITY APPLN. INFO.: US 1999-163269P P 19991103	.03
US 2000-704305 B1 20001102	.02
WO 2000-US30329 W 20001103	.03
US 2002-91949 A3 20020306	306
US 2003-426097 A1 20030429	29

OTHER SOURCE(S):

MARPAT 134:353258

GI

$$R^{6}$$
 R^{7}
 R^{8}
 R^{8}
 R^{8}
 R^{1}
 R^{3}
 R^{2}
 R^{1}

AB Diarylmethyltetrahydroisoquinolines (4R) - or (4S) -I [R1 = (un) substituted alkyl, alkenyl, alkynyl, cycloalkyl; R2 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, haloalkyl; R3 = H, halogen, (un)substituted OH, S(O)nH, CN, CHO, CONH2, alkyl, alkenyl, alkynyl, cycloalkyl; R4 = (un) substituted aryl, heteroaryl; R5-R7 = H, halogen, CN, (un) substituted OH, NH2, S(O)nH, CHO, CONH2, alkyl, alkenyl, alkynyl, cycloalkyl; R8 = H, (un) substituted OH; n = 0-2] were prepared for use as blockers of the reuptake of norepinephrine, dopamine and serotonin (no data). Thus, 3-bromobenzaldehyde is stirred in the presence of methylamine and reduced with sodium borohydride followed by addition of α -chloroacetophenone and reduction of the amino ketone in situ with sodium borohydride to give 3-BrC6H4CH2N(Me)CH2CH(OH)Ph; cyclization of the benzyl alc. with sulfuric acid followed by coupling with phenylboronic acid gave I (R1 = Me; R4 = Ph; R2 = R3 = R5 = R6 = R7 = H) as an oil. Such compds. are particularly useful in the treatment of a neurol. and psychiatric disorders which are created by or are dependent upon decreased availability of serotonin, norepinephrine or dopamine, such as attention deficit-hyperactivity disorder (ADHD), anxiety, depression, and addiction disorders.

IT 338997-66-3P 338997-73-2P 338997-75-4P 338998-19-9P 338998-25-7P 338998-67-7P 338998-67-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diarylmethyltetrahydroisoquinolines as selective reuptake inhibitors of dopamine, norepinephrine, and serotonin)

RN 338998-67-7 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-2-methyl-4-phenyl-7-(3-thienyl)-, (-)-(9CI) (CA INDEX NAME)

Rotation (-).

REFERENCE COUNT:

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

8

ACCESSION NUMBER:

2000:699185 CAPLUS

DOCUMENT NUMBER:

133:267150

TITLE:

Preparation of amino acid sulfonamide derivatives as

inhibitors of aspartyl protease

INVENTOR(S):

Tung, Roger Dennis; Salituro, Francesco Gerald;

Deininger, David D.; Murcko, Mark Andrew; Novak, Perry

Michael; Bhisetti, Govinda Rao

PATENT ASSIGNEE(S):

Vertex Pharmaceuticals, Incorporated, USA

SOURCE:

U.S., 74 pp., Cont.-in-part of U.S. Ser. No. 207,580,

abandoned.

CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PAT	PENT	NO.			KIN	D	DATE		i	APPL	ICAT	ION 1	NO.		D	ATE	
						-									-		
US	6127	372			Α		2000	1003	1	US 1	996-	4243	72		1	9960	401
WO	9524	385			A1		1995	0914	1	WO 1	995-1	US24:	20		1	9950	224
	W:	AM,	ΑT,	AU,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CZ,	DE,	DK,	EE,	ES,	FI,
							KG,										
							NZ,										
		TT,									•	•	•	•	,	•	,
	RW:	KΕ,	MW,	SD,	SZ,	UG,	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙE,	IT,
							BF,										
			TD,										-	•	-	Ť	•
PRIORITY	APP	LN.	INFO	. :					τ	JS 1:	994-:	2075	30	1	B2 1	9940	307
									7	WO 1	995-1	JS24:	20	1	W 1	9950	224

OTHER SOURCE(S): MARPAT 133:267150

Sulfonamides Z-(CH-D)pC(:G)(CXX')mC(:G')N(D')SO2-E' [Z = N(D), SO2E, NH-A, N(D)-A, NH-E, NHC(O)N(D)(E), NH-Ht, N(D)-Ht or phthalimidyl (A = Ht or -R1-Ht, where Ht is a heterocycle which may be substituted, R1 = CO, SO2, COCO, O2C, OSO2, NHSO2, NHCO, NHCOCO, which may be substituted); D, D' = aryl, carbocycle, Ht, alkyl, alkenyl, cycloalkyl, cycloalkenyl, etc.; m = 1-3; p = 0 or 1; G, G' = H2 or O; X, X' = H, OH, NH2, SH, D, halo or XX' = O] were prepared as aspartyl protease inhibitors. Thus, t-BuNHCON(CH2Ph)CH2CH(OH)N(CH2-cyclopentyl)SO2C6H4OMe-p, prepared by sequential reactions of cyclopentylmethylamine, p-methoxybenzenesulfonyl chloride, epibromohydrin, benzylamine, and t-Bu isocyanate, showed Ki = 2,400 for inhibition of HIV-1 protease.

IT 172738-36-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino acid sulfonamide derivs. as inhibitors of aspartyl protease)

RN 172738-36-2 CAPLUS

CN Benzenesulfonamide, N-(cyclopentylmethyl)-N-[3-(3,4-dihydro-1-oxo-4-phenyl-2(1H)-isoquinolinyl)-2-hydroxypropyl]-4-methoxy- (9CI) (CA INDEX NAME)

Ph OH CH2 O N— CH2-CH-CH2-N—S OME

REFERENCE COUNT:

THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:

2000:662935 CAPLUS

DOCUMENT NUMBER:

133:266707

TITLE:

Synthesis of 4-aryl-2-methyl-1,2,3,4-

tetrahydroisoquinolines via Pummerer-type cyclization

of N-(arylmethyl)-N-methyl-2-aryl-2-

(phenylsulfinyl)acetamides

AUTHOR (S):

Toda, Jun; Sonobe, Akihiro; Ichikawa, Tsuyoshi;

Saitoh, Toshiaki; Horiguchi, Yoshie; Sano, Takehiro

CORPORATE SOURCE: Showa Pharm. Univ., Tokyo, 194-8543, Japan

SOURCE:

ARKIVOC [online computer file] (2000), 1(2), 176-190

CODEN: AKVCFI

URL: http://www.arkat.org/arkat/journal/Issue2/ms23/ms

23.pdf

PUBLISHER:

ARKAT Foundation

DOCUMENT TYPE:

Journal; (online computer file)

LANGUAGE: English

OTHER SOURCE(S):

CASREACT 133:266707

GI

L6 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:490065 CAPLUS

DOCUMENT NUMBER: 133:266709

TITLE: 3-Aza-Cope Rearrangement of Quaternary N-Allyl

Enammonium Salts. Stereospecific 1,3 Allyl Migration

from Nitrogen to Carbon on a Tricyclic Template

AUTHOR(S): McComsey, David F.; Maryanoff, Bruce E.

CORPORATE SOURCE: Drug Discovery, R. W. Johnson Pharmaceutical Research

Institute, Spring House, PA, 19477, USA

SOURCE: Journal of Organic Chemistry (2000), 65(16), 4938-4943

CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 133:266709

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

ΔR N-Allyl enamines can undergo a [3,3] sigmatropic rearrangement known as a 3-aza-Cope (or amino-Claisen) reaction. We explored a 3-aza-Cope reaction involving 1,3 allylic migration from nitrogen to carbon in N-allyl enammonium quaternary salts, exemplified by benzo[a]quinolizine I and pyrrolo[2,1-a]isoquinoline II, with an interest in stereochem. and mechanism. Salts I and II were accessed, resp., through stereospecific allylation of hydroxy amines derivs. to give hydroxyammonium salts, which were dehydrated with trifluoroacetic acid. Allylic migration in these tricyclic tetrahydroisoquinolines occurred with high stereospecificity, with the major fused tetrahydroisoquinolines III and IV apparently deriving from a concerted suprafacial [3,3] rearrangement. The rearrangement of I to III was facile at 23 °C (t1/2 = ca. 5 h) and was >98% stereospecific, whereas the rearrangement of II to IV required heating between 50 and 100 °C, with ca. 90-95% stereospecificity (t1/2 = ca. 0.3 h at 100 °C). A deuterium-labeling experiment with a deuterium-labeled analog of II confirmed that allylic inversion accompanies the 1,3 migration en route to a deuterium-labeled analog of IV, supporting the predominance of a concerted [3,3] sigmatropic mechanism. However, the 5-10% loss of stereospecificity in the rearrangements of the pyrroloisoquinolines such as II, reflected by formation of minor stereoisomers of IV, resp., indicates a minor nonconcerted reaction pathway.

IT 297753-48-1P 297753-52-7P 297753-57-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of allyl fused isoquinoline derivs. by stereoselective aza-Cope rearrangement of quaternary N-allyl fused tetrahydroisoquinoline enammonium salts)

RN 297753-48-1 CAPLUS

CN Pyrrolo[2,1-a]isoquinolinium, 1,2,3,5,6,10b-hexahydro-6-hydroxy-6-[4-(methylthio)phenyl]-4-(2-propenyl)-, bromide, (4R,6S,10bR)-rel-(9CI) (CIINDEX NAME)

Relative stereochemistry.

● Br-

REFERENCE COUNT:

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:

1998:376413 CAPLUS

DOCUMENT NUMBER:

129:4527

TITLE:

Additive and Vinylogous Pummerer Reactions of Amido

Sulfoxides and Their Use in the Preparation of

Nitrogen Containing Heterocycles

AUTHOR (S):

Padwa, Albert; Kuethe, Jeffrey T.

CORPORATE SOURCE:

Department of Chemistry, Emory University, Atlanta,

GA, 30322, USA

SOURCE:

Journal of Organic Chemistry (1998), 63(13), 4256-4268

CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER:

American Chemical Society

DOCUMENT TYPE: LANGUAGE: Journal English

N-tert-Bu amido sulfoxides.

AB The α -thiocarbocation generated from the Pummerer reaction of 2-[4-MeC6H4S(:0)]C6H4CH2CONMe undergoes Friedel-Crafts reaction at the γ -carbon with the tethered aromatic ring. Reductive removal of the phenylthio group from the resulting product using Raney nickel occurs in high yield, and the overall reaction represents a new method for the synthesis of a variety of 3-phenyl-substituted oxindoles. Treatment of the related N-benzyl-N-alkyl amido sulfoxide system with trifluoroacetic anhydride affords tetrahydroisoquinolone derivs. The product distribution encountered coincides with the rotamer population of the starting amide. When the N-benzyl-N-Me amide is used, only the normal Pummerer product is In this case, the thionium ion is generated in the wrong conformation for π -cyclization to occur. The corresponding N-tert-Bu amido system, however, exists in a geometric orientation which places the benzylic group in the crucial conformation necessary for π -cyclization, and consequently, the reaction proceeds smoothly. Related cyclization reactions occur in good yield with the corresponding furanyl and cyclohexenyl N-tert-Bu amido sulfoxides. The additive Pummerer reaction of 3-(phenylsulfinyl)-N-benzyl-N-tert-butylacrylamide gave products derived from both 5- and 6-exo trig cyclizations. Intramol. electrophilic aromatic substitution via six-membered ring closure ultimately afforded a dihydropyridone. The competitive process involving ipso attack of the aromatic ring on the thionium ion generates a spiro cyclohexadienyl cation that undergoes fragmentation of the adjacent σ -bond. The resulting acyl iminium ion is converted to N-tert-butyl-2-phenyl-3-(phenylsulfinyl)acrylamide upon aqueous workup. Only cyclizations leading to five-membered rings occur with the corresponding indolyl and alkenyl

172470-09-6P 207349-89-1P 207349-90-4P IT

> RL: SPN (Synthetic preparation); PREP (Preparation) (additive and vinylogous Pummerer reactions of amido sulfoxides in preparation of nitrogen heterocycles)

172470-09-6 CAPLUS RN

3(2H)-Isoquinolinone, 2-(1,1-dimethylethyl)-1,4-dihydro-4-[2-[(4-CN methylphenyl)thio]phenyl] - (9CI) (CA INDEX NAME)

RN207349-89-1 CAPLUS

CN 3(2H)-Isoquinolinone, 2-(1,1-dimethylethyl)-1,4-dihydro-5-methoxy-4-[2-[(4methylphenyl)thio]phenyl] - (9CI) (CA INDEX NAME)

RN 207349-90-4 CAPLUS

CNmethylphenyl)thio|phenyl]- (9CI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS 62 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 8 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:499172 CAPLUS

DOCUMENT NUMBER:

127:176352

TITLE:

Quinolin-2(1H)-ones as NMDA receptor antagonists Ackermann, Karl-august; Gottschlich, Rudolf;

INVENTOR(S): Holzemann, Gunter; Leibrock, Joachim; Rautenberg,

Wilfried; Seyfried, Christoph

Merck Patent G.m.b.H., Germany; Gottschlich, Rudolf; PATENT ASSIGNEE(S):

Holzemann, Gunter; Leibrock, Joachim; Rautenberg,

Wilfried; Seyfried, Christoph

PCT Int. Appl., 43 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

		APPLICATION NO.	
WO 9726244	A1 19970724	WO 1997-EP84	19970110
W: AU, BR, CA, UA, US	CN, CZ, HU, JP,	KR, LT, LV, MX, NO,	PL, RU, SI, SK,
RW: AT, BE, CH,	DE, DK, ES, FI,	FR, GB, GR, IE, IT,	LU, MC, NL, PT, SE
DE 19601782	A1 19970724	DE 1996-19601782	19960119
CA 2243474	AA 19970724	CA 1997-2243474	19970110
		AU 1997-13112	19970110
AU 716230	B2 20000224		
EP 885196	A1 19981223	EP 1997-900586	19970110
R: AT, BE, CH,	DE, DK, ES, FR,	GB, GR, IT, LI, LU,	NL, SE, PT, IE,
SI, LT, LV,	FI		
CN 1211974	A 19990324	CN 1997-192395	19970110
BR 9707027	A 19990720	BR 1997-7027	19970110
JP 2000503308		JP 1997-525656	19970110
ZA 9700364	A 19970722	ZA 1997-364	19970116
NO 9803333	A 19980918	NO 1998-3333	19980717
US 6028080		US 1998-101837	
PRIORITY APPLN. INFO.:		DE 1996-19601782	A 19960119
		WO 1997-EP84	W 19970110
OTHER SOURCE(S):	MARPAT 127:17635	52	

AB Quinolinones I [R = substituted Ph; R1, R2 = H, halogen, alkyl, alkoxy] were prepared fo use in treating neurodegenerative disorders (no data). Thus, the quinolinone II and its enantiomers were obtained from 2-BrCH2COC6H4CH2CO2Me in 9 steps.

IT 193819-37-3P 193819-40-8P 193819-43-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylquinolinones as NMDA receptor antagonists)

RN 193819-37-3 CAPLUS

2(1H)-Quinolinone, 7-chloro-4-hydroxy-3-[3-(1,2,3,4-tetrahydro-2-methyl-4-CN isoquinolinyl)phenyl]-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

RN 193819-43-1 CAPLUS

CN 2(1H)-Quinolinone, 7-chloro-4-hydroxy-3-[3-(1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, (R)-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 193819-42-0 CMF C25 H21 Cl N2 O2

Absolute stereochemistry.

CM 2

CRN 75-75-2 CMF C H4 O3 S

6 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:

1996:644882 CAPLUS

DOCUMENT NUMBER:

125:292276

TITLE:

4-(3,4-Dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. II. Their renal vasodilation activity and

structure-activity relationship

AUTHOR (S):

Anan, Hideki; Tanaka, Akihiro; Tsuzuki, Ryuji; Yokota,

Masaki; Yatsu, Takeyuki; Fujikura, Takashi

CORPORATE SOURCE:

Inst. Drug Discovery Res., Yamanouchi Pharmaceutical

Co., Ltd., Ibaraki, 305, Japan

SOURCE:

Chemical & Pharmaceutical Bulletin (1996), 44(10),

1865-1870

CODEN: CPBTAL; ISSN: 0009-2363

PUBLISHER: DOCUMENT TYPE:

Pharmaceutical Society of Japan Journal

LANGUAGE:

English

A series of 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivs. AB showed potent DA1 agonistic activities. We investigated the structure-activity relation of the racemic compds. of this series. 4-(3,4-Dihydroxyphenyl)-7-methanesulfonamido-1,2,3,4tetrahydroisoquinoline (43) was identified as a potent renal vasodilator with activity almost equal to that of YM435 (1).

IT 182958-00-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(dihydroxyphenyltetrahydroisoquinoline derivs. and their renal vasodilation activity and structure-activity relationship)

RN 182958-00-5 CAPLUS

Methanesulfonamide, N-[4-(3,4-dimethoxyphenyl)-1,2,3,4-tetrahydro-7-CNmethoxy-2-(phenylmethyl)-8-isoquinolinyl]- (9CI) (CA INDEX NAME)

ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:

1995:995626 CAPLUS

DOCUMENT NUMBER:

124:145926

TITLE:

Preparation of aminoalkylisochromans, -isoquinolines,

and related compounds as gonadotropin-releasing hormone antagonists, calcium antagonists, and/or

monoamine uptake inhibitors.

INVENTOR (S):

Kato, Kaneyoshi; Sugiura, Yoshihiro; Kato, Koichi;

Nagai, Yasuo

PATENT ASSIGNEE(S):

Takeda Chemical Industries, Ltd., Japan

SOURCE: Eur. Pat. Appl., 104 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 679642	A1	19951102	EP 1995-106189	19950426
EP 679642	B1	19991110		
R: AT, BE, CH,	DE, DK	, ES, FR, C	GB, GR, IE, IT, LI, LU,	NL, PT, SE
US 5607939	A	19970304	US 1995-428499	19950425
AT 186530	E	19991115	AT 1995-106189	19950426
CA 2148047	AA	19951029	CA 1995-2148047	19950427
JP 08012650	A2	19960116	JP 1995-103389	19950427

US 5654296 A 19970805 US 1996-760904 19961206
PRIORITY APPLN. INFO.: JP 1994-114054 A 19940428
JP 1994-92769 A 19940428
US 1995-428499 A3 19950425

OTHER SOURCE(S): MARPAT 124:145926

Ι

GΙ

AB Title compds. (I; Ar = aromatic group; R1, R2, R3 = H, acyl, hydrocarbyl; R1R2N = heterocyclyl; m = 1-6; n = 2, 3; dotted line = optional double bond; X = 0, NR3, N:), were prepared Thus, 4-(2-iodoethyl)-4- phenylisochroman and imidazole were stirred with K2CO3 in MeCN for 4 days at 60° to give 4-phenyl-4-[2-(1-imidazolyl)ethyl] isochroman, isolated as the hydrochloride. I inhibited 5-HT uptake in rat brain prepns. with IC50 = $0.03-1.0~\mu M$. I drug formulations are given.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminoalkylisochromans, -isoquinolines, and related compds. as gonadotropin-releasing hormone antagonists, calcium antagonists, and/or monoamine uptake inhibitors)

RN 173272-41-8 CAPLUS

CN Thiourea, N-phenyl-N'-[3-(1,2,3,4-tetrahydro-2-methyl-4-phenyl-4-isoquinolinyl)propyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:

1995:994876 CAPLUS

DOCUMENT NUMBER:

124:116874

TITLE:

Preparation of sulfonamide derivatives as aspartyl

protease inhibitors

INVENTOR(S):

Tung, Roger Dennis; Salituro, Francesco Gerald;

Deininger, David D.; Murcko, Mark Andrew; Novak, Perry

Michael; Bhisetti, Govinda Rao

PATENT ASSIGNEE(S):

Vertex Pharmaceuticals Inc., USA

SOURCE:

PCT Int. Appl., 211 pp.

CODEM. DIVVI

DOCUMENT TYPE:

CODEN: PIXXD2

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

GΙ

RN

PAT	rent 1	NO.			KIN)	DATE			APPL	ICAT	ION	NO.		D.	ATE		
	9524															9950:	224	
	W:	AM,	AT,	AU,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CZ,	DE,	DK,	EE,	ES,	FI,	
		GB,	GE,	HU,	JP,	KE,	KG,	KΡ,	KR,	ΚZ,	LK,	LR,	LT,	LU,	LV,	MD,	MG,	
		MN,	MW,	MX,	NL,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	TJ,	
		TT,	UA															
	RW:	ΚE,	MW,	SD,	SZ,	ŪĠ,	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙE,	IT,	
		LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	ML,	MR,	ΝE,	
		SN,	TD,	TG														
CA	2183	653			AA		1995	0914	(CA 1	995-	2183	653		1	9950	224	
	9519						1995											
	6994						1998											
EP	74942	21			A1		1996	1227	:	EP 1	995-	9119	60		1	9950	224	
EP	74942	21			B1		1999	0915										
	R:	ΑT,	ΒE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙE,	IT,	LI,	LU,	MC,	NL,	PT,	SE
CN	1146	201			Α		1997	0326	(CN 1	995-	1924	73		1	9950	224	
	1050				T2		1998											
AT	1845	94			E		1999	1015	i	AT 1	995-	9119	60		1:	9950	224	
ES	2139	195			Т3		2000	0201	1	ES 1	995-:	9119	60		1	9950	224	
ZA	9501	688			Α		1995				995-							
US	6127	372	·		A		2000	1003	1	JS 1	996-	4243	72		1:	9960	401	
HK	1012	622			A1		2000	0922	1	HK 1	998-	1139	72		1:	9981	217	
GR	3032	151			Т3		2000	0427	(GR 1	999-	4032	37		1:	9991	215	
PRIORITY	(APP	LN.]	INFO	. :							994-							
										VO 1	995-1	US24:	20	1	W 1	9950	224	
OTHER SO	OURCE	(S):			MARI	TAS	124:	1168	74									

$$\begin{array}{c|c} Ph & O & H & O \\ \hline O & CHMe_2 & OH \\ \hline O & CHMe_2 & Ph \\ \end{array} \\ \begin{array}{c|c} SO_2 & OMe \\ \hline \end{array}$$

AB Z(CHD)pC(:G)(CXX')mC(:G')ND'SO2E' [D,D' = aryl, heterocyclyl, NH2, alkyl,
 etc.; E,E' = OH, NH2, aryl, heterocyclyl, etc.; G,G' = H2, O; X,X' = H,
 oh, NH2, halo, etc.; XX' = O; Z = NDSO2E, NHA, NHE, heterocyclyl, etc.; A
 = H, (cyclo)alkyl, Ph, heterocyclyl, etc.; m = 1-3; p = 0 or 1] were
 prepared Title compound I had Ki of 7nM against HIV-1 protease.
IT 172738-36-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

I

(preparation of sulfonamide derivs. as aspartyl protease inhibitors) 172738-36-2 CAPLUS

CN Benzenesulfonamide, N-(cyclopentylmethyl)-N-[3-(3,4-dihydro-1-oxo-4-phenyl-2(1H)-isoquinolinyl)-2-hydroxypropyl]-4-methoxy- (9CI) (CA INDEX NAME)

L6 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:865227 CAPLUS

DOCUMENT NUMBER: 124:86784

TITLE: Vinylogous Pummerer Reaction of Amido-Substituted

Sulfoxides as a Method for Preparing Oxindoles and

Tetrahydroisoquinolones

AUTHOR(S): Kuethe, Jeffrey T.; Cochran, John E.; Padwa, Albert

CORPORATE SOURCE: Department of Chemistry, Emory University, Atlanta,

GA, 30322, USA

SOURCE: Journal of Organic Chemistry (1995), 60(22), 7082-3

CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 124:86784

The α -thiocarbocation generated from the Pummerer reaction of N-Me N-phenyl-2-[2-(toluene-4-sulfinyl)phenyl]acetamide undergoes Friedel-Crafts reaction at the γ -C by the tethered π -bond. Reductive removal of the phenylthio group from the resulting product using Raney Ni occurs in high yield and the overall reaction represents a new method to synthesize a variety of 3-Ph substituted oxindoles. Treatment of the related N-benzyl-N-alkyl amido sulfoxide system with trifluoroacetic anhydride affords tetrahydroisoguinolone derivs. product distribution encountered coincides with the rotamer population of the starting amide. When the N-benzyl-N-Me amide was used, only the normal Pummerer product is formed. In this case, the thionium ion is generated in the wrong conformation for π -cyclization, and none occurs. The corresponding N-tert-Bu amido system, however, exists in a geometric orientation which places the benzylic group in the crucial conformation necessary for π -cyclization and, consequently, the reaction occurs smoothly. Related cyclization reactions occur in good yield with the corresponding furanyl and cyclohexenyl N-tert-Bu amido sulfoxides.

IT 172470-09-6P

CN

RL: SPN (Synthetic preparation); PREP (Preparation)

(vinylogous Pummerer reaction for cyclization of amido-substituted sulfoxides in preparation of oxindoles and tetrahydroisoquinolones)

RN 172470-09-6 CAPLUS

3(2H)-Isoquinolinone, 2-(1,1-dimethylethyl)-1,4-dihydro-4-[2-[(4-methylphenyl)thio]phenyl]- (9CI) (CA INDEX NAME)

CAPLUS COPYRIGHT 2005 ACS on STN ANSWER 13 OF 15

ACCESSION NUMBER: 1985:523465 CAPLUS

DOCUMENT NUMBER: 103:123465

TITLE: Pyridoindole derivatives and their use

INVENTOR(S): Boltze, Karl Heinz; Davies, Margaret A.; Junge, Bodo;

Schuurman, Teunis; Traber, Joerg

PATENT ASSIGNEE(S): Troponwerke G.m.b.H. und Co. K.-G., Fed. Rep. Ger.

SOURCE: Ger. Offen., 62 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 3333994	A1	19850404	DE 1983-3333994		19830921
EP 140070	A1	19850508	EP 1984-110732		19840908
R: AT, BE, CH,	DE, FR	, GB, IT,	LI, NL, SE		
US 4564613	A	19860114	US 1984-651001		19840914
AU 8433201	A1	19850328	AU 1984-33201		19840917
ES 536003	A1	19851216	ES 1984-536003		19840918
FI 8403672	A	19850322	FI 1984-3672		19840919
DK 8404487	Α	19850322	DK 1984-4487		19840920
JP 60087256	A2	19850516	JP 1984-195859		19840920
ZA 8407400	A	19850626	ZA 1984-7400		19840920
HU 36119	0	19850828	HU 1984-3541		19840920
ES 545270	A1	19860316	ES 1985-545270		19850716
PRIORITY APPLN. INFO.:			DE 1983-3333994	Α	19830921
OTHER SOURCE(S):	CASREA	CT 103:12	3465		
CT.					

I

GI

AB The title compds. (I; R = H, alkyl aminoalkyl, heterocyclylalkyl; RR1 = O, OCH2CH2O, SCH2CH2S; RR3 = atoms required to complete a 6-membered N-containing ring; R1R2 = H, bond; R2R3 = O; R2R4 = bond,; R4 = H, alkyl, iminomethyl, heterocyclyl; R5 = H, alkyl; R6 = halo) were prepared Thus,

IT

2-H2NC6H4CH2NMeCH2CHPhOH was condensed with Cl3CCH(OH)2 and HONH2.HCl to give 91% 2-HON: CHCONHC6H4CH2NMeCH2CHPhOH. This was cyclized by stirring at 35° in concentrated H2SO4 to give 90% I (RR1 = R2R3 = O, R4 = R6 = H, R5 = Me). This was treated with LiAlH4 in Et2O-THF at room temperature to give 30% I (R = R3 = R4 = R6 = H, R1R2 = bond, R5 = Me) (II). II inhibited tetrabenazine-induced ptosis in mice with an ED50 of 0.3 mg/kg i.p.

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and condensation of, with piperidine)

RN 98159-59-2 CAPLUS

Spiro[1,3-dioxolane-2,3'-[3H]pyrrolo[3,2-h]isoquinoline]-2'(1'H)-thione, CN 6',7',8',9'-tetrahydro-8'-methyl-6'-phenyl- (9CI) (CA INDEX NAME)

ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN 1.6

ACCESSION NUMBER:

1985:62095 CAPLUS

DOCUMENT NUMBER:

102:62095

TITLE:

Optical antipodes of 8-amino-4-phenyl-1,2,3,4-

tetrahydroisoquinoline and pharmaceuticals containing

them with an antidepressive action

INVENTOR(S):

Schmitt, Karl; Kruse, Hansjoerg; Schacht, Ulrich;

Kunstmann, Rudolf

PATENT ASSIGNEE(S):

Hoechst A.-G., Fed. Rep. Ger.

SOURCE:

Ger. Offen., 8 pp.

DOCUMENT TYPE:

CODEN: GWXXBX

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PAT	ENT :	NO.			KINI)	DATE		AP	PLICA'	TION I	NO.		DATE
							-							_	
	DE .	3310	878			A1		1984	0927	DE	1983	-33108	378		19830325
	DK	8401	447			Α		1984	0926	DK	1984	-1447			19840229
	EΡ	1204	38			A1		1984	1003	EP	1984	-10302	21		19840320
		R:	AT,	BE,	CH,	DE,	FR	, GB,	ΙT,	LI, L	J, NL	, SE			
	JP	5917	6260			A2		1984	1005	JP	1984	-54620)		19840323
	ES .	5309	05			A1		1985	0416	ES	1984	-53090)5		19840323
PRIOR	RITY	APP	LN.	INFO	. :					DE	1983	-33108	378	Α	19830325
GT															

Ι

AB The antidepressant (no data) racemic title compound (I) was separated into its enantiomers by crystallization of its salt with

N-(phenylsulfonyl)-L-(+)-glutamic

acid.

IT 94532-83-9P 94532-84-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and decomposition of)

RN 94532-83-9 CAPLUS

CN L-Glutamic acid, N-(phenylsulfonyl)-, compd. with (R)-1,2,3,4-tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine (9CI) (CA INDEX NAME)

CM 1

CRN 89664-20-0 CMF C16 H18 N2

Absolute stereochemistry.

CM 2

CRN 20531-36-6 CMF C11 H13 N O6 S

Absolute stereochemistry.

RN 94532-84-0 CAPLUS

CN L-Glutamic acid, N-(phenylsulfonyl)-, compd. with (S)-1,2,3,4-tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine (9CI) (CA INDEX NAME)

CM 1

CRN 89664-18-6 CMF C16 H18 N2

Absolute stereochemistry.

CM 2

CRN 20531-36-6 CMF C11 H13 N O6 S

Absolute stereochemistry.

L6 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:

1982:104179 CAPLUS

DOCUMENT NUMBER:

96:104179

TITLE:

Preparation of condensed 2-alkylthio-4-

hydroxypyrimidines

AUTHOR (S):

Haede, Werner

CORPORATE SOURCE:

Hoechst A.-G., Frankfurt/Main, D-6230/80, Fed. Rep.

Ger.

SOURCE:

Journal of Heterocyclic Chemistry (1981), 18(7),

1417-19

CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE:

Journal

LANGUAGE:

German

OTHER SOURCE(S):

CASREACT 96:104179

GI

AB The condensed pyrimidines I, II (R = Me, Cl), and III were prepared by cyclization of a S-allylisothioureas. Thus, heating the isothiourea IV 1 h at 175° gave 93% II (R = Cl).

IT 80947-23-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

ΙI

(preparation and hydrolysis of)

RN 80947-23-5 CAPLUS

CN Pyrido[4,3-h]quinazolin-4(1H)-one, 2-(ethylthio)-7,8,9,10-tetrahydro-9-methyl-7-phenyl- (9CI) (CA INDEX NAME)

=> d his


L6

(FILE 'HOME' ENTERED AT 12:12:05 ON 04 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:15 ON 04 MAR 2005
L1 STRUCTURE UPLOADED
L2 29 S L1
L3 1211694 S 4-7/NR AND 1-4/N AND 0-5/O AND 0-3/S
L4 4 S L1 SAM SUB=L3
L5 62 S L1 FULL SUB=L3

FILE 'CAPLUS' ENTERED AT 12:14:21 ON 04 MAR 2005 15 S L5

=> d ll L1 HAS NO ANSWERS L1 STR



Structure attributes must be viewed using STN Express query preparation.

=>

PALM INTRANET

Day: Friday Date: 3/4/2005 Time: 12:27:49

Inventor Name Search Result

Your Search was:

Last Name = BECK First Name = JAMES

				·	
Application#	Patent#	Status	Date Filed	Title	Inventor Name
08726511	5829611	150	10/07/1996	TAMPER-EVIDENT OVERCAP	BECK, JAMES M.
08728832	5829609	250	10/10/1996	TWIST TOP CHILD-RESISTANT CLOSURE	BECK, JAMES M.
08745891	5817082	150	11/08/1996	MEDICAMENT CONTAINER CLOSURE WITH INTEGRAL SPIKE ACCESS MEANS	BECK, JAMES M.
08761395	5743444	150	12/06/1996	TWIST DISPENSING CLOSURE	BECK, JAMES M.
<u>09027126</u>	6024256	150	02/20/1998	TAMPER-EVIDENT CLOSURE	BECK, JAMES M.
09059089	5842592	150		TAMPER-EVIDENT SNAP ON CAP WITH TEAR LEVER	BECK, JAMES M.
09081811	5996859	150	05/20/1998	HINGED DISPENSING CLOSURE	BECK, JAMES M.
29002724	D355119	150	12/17/1992	CAP FOR CONTAINER	BECK, JAMES M.
<u>29104779</u>	D419069	150		CLOSURE FOR DISPENSING NOZZLE	BECK, JAMES M.
<u>09904384</u>	Not Issued	161		PROCESSES FOR DECOMPOSITION OF HALOGENATED COMPOUNDS	BECK, JAMES N.
60217412	Not Issued	159		NOVEL 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES THERAPEUTIC USE THEREOF	BECK, JAMES P
<u>09704305</u>	Not Issued	161		ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USES THEREOF	BECK, JAMES P.
<u>09704306</u>	Not Issued	071			BECK, JAMES P.
<u>09738666</u>	Not	092	12/15/2000	NOVEL IMIDAZOPYRIMIDINYL	BECK, JAMES

. ·	Issued	I		AND IMIDAZOPYRI DINYL	P.
	Issued			DERIVATIVES	1.
09789673	6525056	150	02/21/2001	HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS	BECK, JAMES P.
09895843	6846813	150	06/29/2001	COMPOUNDS TO TREAT ALZHEIMER'S DISEASE	BECK, JAMES P.
<u>09896139</u>	Not Issued	071	06/29/2001	COMPOUNDS TO TREAT ALZHEIMER'S DISEASE	BECK, JAMES P.
09902845	Not Issued	071	07/11/2001	NOVEL 4-PHENYL SUBSTITUTED TETRAHYDROISO QUINOLINES THERAPEUTIC USE THEREOF	BECK, JAMES P.
10091949	6579885	150	03/06/2002	ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF	BECK, JAMES P.
10170331	Not Issued	071	06/13/2002	MACROCYCLES USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE	BECK, JAMES P.
10171182	Not Issued	071	06/12/2002	MYCROCYCLES USEFUL IN THE TEATMENT OF ALZHEIMER'S DISEASE	BECK, JAMES P.
10426097	Not Issued	041	04/29/2003	ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF	BECK, JAMES P.
<u>10427106</u>	Not Issued	041	04/30/2003	HYDROXYPROPYL AMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE	BECK, JAMES P.
10482098	Not Issued	030	07/23/2004	USE OF BICYCLO COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE	BECK, JAMES P.
10494184	Not Issued	030	08/27/2004	HYDROXY SUBSTITUTED AMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE	BECK, JAMES P.
10658959	Not Issued	041		ACETYL 2-HYDROXY-1, 3- DIAMINOALKANES	BECK, JAMES P.
10724856	Not Issued	030		USE OF ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES IN THE TREATMENT OF CHRONIC AND NEUROPATHIC PAIN,	BECK, JAMES P.

_				·	
				MIGRAINE HEADACHES, AND URGE, STRESS AND MIXED URINARY INCONTINENCE	
10724857	Not Issued	030	12/01/2003	USE OF 4-PHENYL-SUBSTITUTED TETRAHYDROISOQUINOLINES IN THE TREATMENT OF PAIN, MIGRAINE HEADACHES AND URINARY INCONTINENCE	BECK, JAMES P.
10725221	Not Issued	030	12/01/2003	USE OF 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES IN THE TREATMENT OF PAIN, MIGRAINE AND URINARY INCONTINENCE	
<u>10917801</u>	Not Issued	020	08/13/2004	ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF	BECK, JAMES P.
60297505	Not Issued	159	06/12/2001	COMPOUNDS TO TREAT ALZHEIMER'S DISEASE	BECK, JAMES P.
60297540	Not Issued	159	06/12/2001	COMPOUNDS TO TREAT ALZHEIMER'S DISEASE	BECK, JAMES P.
60297546	Not Issued	159	06/12/2001	COMPOUNDS TO TREAT ALZHEIMER'S DISEASE	BECK, JAMES P.
60318014	Not Issued	159	09/07/2001	NOVEL IMIDAZOLE, OXAZOLE, AND THIAZOLE DERIVATIVES AND THEIR USES AS CRF MODULATORS	BECK, JAMES P.
60318016	Not Issued	159	09/07/2001	NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE AS CRF MODULATORS	BECK, JAMES P.
60318030	Not Issued	159	09/07/2001	NOVEL PYRAZINES DERIVATIVES AND THEIR USE AS CRF MODULATORS	BECK, JAMES P.
60318031	Not Issued	159	09/07/2001	NOVEL IMIDAZOLE, OXAZOLE, AND THAZOLE DERIVATIVES AND THEIR USE AS CRF MODULATORS	BECK, JAMES P.
60318032	Not Issued	159	09/07/2001	NOVEL, PYRAZOLE, ISOXAZOLE, AND ISOTHIAZOLE DERIVALTIVES AND THEIR USE AS CRF MODULATORS	BECK, JAMES P.
60318034	Not Issued	159		NAVEL PYRIDONE DERIVATIVEAS AND THEIR USE AS CRF MODULATORS	BECK, JAMES P.
60318036	Not Issued	159		NOVEL FUSED HETEROCYCLES AND THEIR USE AS CRF	BECK, JAMES P.

				MODULATORS	
60318077	Not Issued	159	09/07/2001	NOVEL PYRIDINE DERIVATIVES AND THEIR USE AS CRF MODULATORS	BECK, JAMES P.
60318090	Not Issued	159	09/07/2001	NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE AS CRF MODULATORS	BECK, JAMES P.
60318092	Not Issued	159	09/07/2001	NOVEL FUSED PYRAZINE DERIVATIVES AND THEIR USE AS CRF MODULATORS	BECK, JAMES P.
60318188	Not Issued	159	09/07/2001	NOVEL 3- AND 6- ARYLPYRAZINE-2(1H)-ONE DERIVATIVES AND THEIR USE AS CRF MODULATORS	BECK, JAMES P.
60323176	Not Issued	159	09/18/2001	NOVEL 3-ARYLPYRIDAZINE DERIVATIVES AND THEIR USE AS CNS RECEPTOR MODULATORS	BECK, JAMES P.
60324343	Not Issued	159	:	NOVEL ISOTHIAZOLO[5,4-C] PYRIDINES AND ISOTHIAZOLO [4,5-C]PYRIDINES AND THEIR USE AS NEUROTRANSMITTER MODULATORS	BECK, JAMES P.
60324384	Not Issued	159		NOVEL 2-ARYLPYRIMIDINO AND 2-ARYLPYRIDINO DERIVATIVES AND THEIR USE AS NEUROTRANSMITTER MODULATORS	BECK, JAMES P.
60332863	Not Issued	159		AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE	BECK, JAMES P.
60351152	Not Issued	159	10/29/2001	HYDROXY SUBSTITUTED AMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE	BECK, JAMES P.
60409565	Not Issued	159	09/10/2002	SUBSTITUTED AMINOETHERS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE	BECK, JAMES P.

Search and Display More Records.

Saarah Anathani Invantari	Last Name	First Name	
Search Another: Inventor	Beck	James	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page